Zebrafish Disease Model Generation

Precision Knockouts for Loss-of-Function Target Validation

Key Features:

• CRISPR-Cas9 RNP Delivery — Optimized sgRNA design with computational off-target prediction; high-efficiency ribonucleoprotein injection into single-cell embryos.
• Rigorous Genotype-to-Phenotype Validation — HRM analysis and Sanger sequencing confirm frameshift deletions; germline transmission screening validates heritable lines, not mosaic founders.
• Ideal For — Loss-of-function target validation; essential gene viability studies; comparative phenotyping against wild-type and heterozygous siblings.

Explore the Power of Screening-Ready Knockouts:

For virtual biotechs validating a novel target, a null mutant generated in 8–10 weeks provides in vivo evidence of target engagement and disease relevance before you commit to rodent model development. For pharma teams, our standardized phenotyping protocols deliver survival curves, behavioral endpoints, and organ-specific readouts that integrate directly into target validation and lead optimization decision gates. Every null mutant is delivered with complete genotype documentation and off-target validation sequencing—data you can defend to your CSO and your reviewers.

Human Disease Alleles in a Vertebrate Context

Key Features:

• Precision Knock-in via HDR — Site-directed knock-in of human patient mutations, disease-associated SNPs, or structural variants into the zebrafish ortholog using homology-directed repair templates.
• Allele-Specific Phenotyping — Comparative analysis of patient-variant lines against wild-type and null backgrounds, enabling allele-specific rescue studies and variant pathogenicity scoring.
• Ideal For — Patient-specific disease modeling; rare genetic disorder validation; variant-of-unknown-significance (VUS) functional characterization.

Why It Matters:

Patient-variant models transform zebrafish from a generic tool into a precision medicine platform. For biotechs developing allele-specific therapies, we generate the exact variant you need to test compound selectivity. For pharma teams exploring genetically defined patient subpopulations, our knock-in lines provide preclinical validation of target-disease linkage with human-relevant alleles—not just gene-level knockouts. The HDR template design and phenotypic rescue screening are managed by the same project team, ensuring variant fidelity from construct to behavior.

Real-Time In Vivo Visualization of Disease and Drug Response

Key Features:

• Tissue-Specific Fluorescent Reporters — Custom transgenic lines with tissue-specific promoters (neuronal, cardiac, vascular, hepatic) and photon-quantifiable reporters for intravital live imaging.
• Cre-lox Lineage Tracing — Inducible recombination systems for temporal control of gene expression and cell-fate tracking during disease progression or drug treatment.
• Ideal For — Real-time drug response tracking; cell-type-specific toxicity assessment; developmental toxicity and teratogenicity screening.

How It Works:

Transgenic reporters turn disease progression and drug response into observable, quantifiable light signals. For cardiotoxicity programs, cardiac-specific GFP lines reveal arrhythmia and morphogenesis defects in real time. For neurodegeneration models, neuronal reporters quantify axonal degeneration and synaptic loss without terminal sampling. These lines integrate directly into our high-content screening workflow, enabling compound evaluation at 96-well scale with sub-millimeter resolution.

Standardized, Quantifiable Disease Endpoints

Key Features:

• Behavioral & Locomotor Profiling — Automated larval tracking (distance, velocity, thigmotaxis) under alternating light-dark cycles; standardized protocols for motor deficit quantification.
• Organ-Specific Imaging & Morphometrics — Fluorescence microscopy and confocal imaging for cardiac morphogenesis, vascular patterning, neuroanatomical quantification, and tumor burden assessment.
• Ideal For — Motor neuron disease validation; cardiovascular defect scoring; oncology xenograft monitoring; developmental toxicity phenotyping.

What We Offer:

Phenotypic validation is where most zebrafish CROs stop at gross morphology. We deliver standardized, statistically powered endpoint datasets: survival curves with Kaplan-Meier analysis, locomotor time-series with genotype stratification, and organ-specific morphometrics with automated image analysis. For ALS models, this means quantified motor deficits that correlate with human disease severity. For oncology programs, this means tumor volume tracking and metastasis scoring. Every dataset is delivered with full statistical documentation and QC metrics—formatted for direct inclusion in IND packages and investor data rooms.